Aridis Pharmaceuticals Inc. (NASDAQ: ARDS) is -28.81% lower on its value in year-to-date trading and has touched a low of $0.68 and a high of $2.94 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The ARDS stock was last observed hovering at around $1.17 in the last trading session, with the day’s loss setting it -0.33% off its average median price target of $10.50 for the next 12 months. It is also 95.58% off the consensus price target high of $19.00 offered by 2 analysts, but current levels are 58.0% higher than the price target low of $2.00 for the same period.
Currently trading at $0.84, the stock is -31.28% and -19.83% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 9.93 million and changing -28.21% at the moment leaves the stock -33.06% off its SMA200. ARDS registered -47.50% loss for a year compared to 6-month loss of -26.96%.
The stock witnessed a -18.45% gain in the last 1 month and extending the period to 3 months gives it a -16.00%, and is -35.38% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 45.12% over the week and 23.32% over the month.
Aridis Pharmaceuticals Inc. (ARDS) has around 34 employees, a market worth around $18.93M and $2.90M in sales. Distance from 52-week low is 23.08% and -71.43% from its 52-week high. The company has generated returns on investments over the last 12 months (591.40%).
Aridis Pharmaceuticals Inc. (ARDS) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Aridis Pharmaceuticals Inc. (ARDS) is a “Buy”. 2 analysts offering their recommendations for the stock have an average rating of 2.30, where 0 rate it as a Hold and 0 think it is a “Overweight”. 2 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Aridis Pharmaceuticals Inc. is expected to release its quarterly report on 05/16/2023.The EPS is expected to shrink by -54.70% this year.
Aridis Pharmaceuticals Inc. (ARDS) Top Institutional Holders
The shares outstanding are 17.70M, and float is at 17.60M with Short Float at 0.55%.
Aridis Pharmaceuticals Inc. (ARDS) Insider Activity
A total of 0 insider transactions have happened at Aridis Pharmaceuticals Inc. (ARDS) in the last six months, with sales accounting for 0 and purchases happening 0 times.